Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.

Biotechnology

Education

Akero

Akero's headquarters in South San Francisco, CA, United States

Andrew Cheng

Meena Jain

Whitney Withington

Valerie Fenster

Brittany de Temple

Arin Bose

Jessie Yan

Thomas Quinn

Yasmine Rafidi

Thomas Ross

Scott Gangloff

Maribel Rios

Libette Luce

Tim Rolph

Catriona Yale

Judy Chou

Mark Iwicki

Seth L. Harrison

Tom Heyman

Yuan Xu

Jane Pritchett Henderson

This department oversees the planning, execution, and management of clinical trials.

Clinical Operations

The Clinical Research and Development team at Akero Therapeutics is responsible for designing, conducting, and overseeing clinical trials aimed at evaluating the safety and efficacy of efruxifermin (EFX) as a treatment for non-alcoholic steatohepatitis (NASH). This interdisciplinary team manages all aspects of clinical program execution, including protocol development, data management, statistical analysis, and ensuring regulatory compliance to advance Akero's drug candidates through the clinical pipeline.

Clinical Research and Development

This department provides strategic direction and oversight for the organization's overall operations and initiatives.

Executive Leadership

This department oversees the planning and execution of clinical programs to advance medical research and product development.

Clinical Development

The Development Team at Akero Therapeutics is responsible for advancing the company's lead product candidate, efruxifermin (EFX), through the clinical development process. This includes overseeing the drug substance process development, managing clinical trial operations, developing medical devices related to the treatment, and ensuring optimal packaging and usability. The team, led by experienced leaders in drug development and engineering, focuses on translating research breakthroughs into effective, approved therapies for non-alcoholic steatohepatitis (NASH).

Development Team

This department is responsible for strategic oversight and ensuring compliance with regulatory and governance standards.

Akero

Org chart

Board & advisors

Teams

Clinical Operations

Clinical Research and Development

Executive Leadership

Clinical Development

Development Team

Governance and Oversight

Offices

Akero

Org chart

Board & advisors

Teams

Clinical Operations

Clinical Research and Development

Executive Leadership

Clinical Development

Development Team

Governance and Oversight

Offices

Related companies